S-ClassAbout S-Class
G
GSKAI Stock Diagnostic Report
GSK Non-GAAP EPS of £0.51 beats by £0.02, revenue of £8.41B beats by £4.05B; reaffirms FY2026 outlook
GSK reported quarterly results that exceeded expectations and reaffirmed its 2026 full-year outlook.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$51.98Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
02
FUNDAMENTALS
Financial & Fundamental Analysis
Non-GAAP EPS £0.51 (above £0.02) and revenue £8.41B recorded, specialty pharmaceuticals (+14%), respiratory/immune/inflammation (+19%), oncology (+17%), HIV (+10%) etc showing high growth across all business segments and reaffirming FY2026 guidance.
03
TECHNICAL VIEW
Technical Position & Response Criteria
Due to the recent 7-day downward trend and an RSI of 47.5, which places it in neutral territory, entry is recommended after confirming support from the moving average alignment.
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Demonstrated fundamental resilience through solid revenue growth in key business units (specialty units (specialty, vaccines, oncology, etc.) and reaffirmation of the FY2026 annual outlook.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-07-28)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.